Market Overview

Cytokinetics Reports Added Safety, Pharmacodynamic Results from ATOMIC-AHF Study


Cytokinetics, Incorporated (NASDAQ: CYTK) today announced the presentation of additional data from the ATOMIC-AHF (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure) clinical trial at a Late Breaking Clinical Trials Session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Orlando, Florida.  The presentation was made by John R. Teerlink, MD, Director of the Heart Failure Program and of the Clinical Echocardiography Laboratory at the San Francisco Veterans Affairs Medical Center, Professor of Medicine at University of California San Francisco and the Principal Investigator in ATOMIC-AHF.   ATOMIC-AHF was a randomized, double-blind, placebo-controlled Phase II clinical trial that enrolled 613 patients hospitalized with acute heart failure (AHF) treated for 48 hours with an intravenous formulation of omecamtiv mecarbil or placebo and designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and potential efficacy of omecamtiv mecarbil in patients with AHF.  Data presented at HFSA included details of the adjudicated myocardial infarctions in ATOMIC-AHF and additional data from the pharmacokinetic/pharmacodynamic relationship between increasing concentrations of omecamtiv mecarbil and increases in echocardiographic measurements of

See full press release

Posted-In: News


Related Articles (CYTK)

View Comments and Join the Discussion!